Literature DB >> 19542449

IL-23 promotes the production of IL-17 by antigen-specific CD8 T cells in the absence of IL-12 and type-I interferons.

Meredith M Curtis1, Sing Sing Way, Christopher B Wilson.   

Abstract

In contrast to CD4 T cells, CD8 T cells inherently differentiate into IFN-gamma-producing effectors. Accordingly, while generation of IFN-gamma-producing Th1 CD4 T cells was profoundly impaired in mice deficient for both type-I IFN and IL-12 signaling in response to infection with Listeria monocytogenes, generation of Ag-specific, IFN-gamma-producing CD8 T cells was unimpaired. However, a fraction of these CD8 T cells also produced IL-17 in an IL-23-dependent manner. Furthermore, the addition of IL-23 in vitro was sufficient for some naive CD8 T cells to differentiate into IFN-gamma/IL-17 dual-producing cells and was associated with increased expression of ROR-gammat and ROR-alpha. Addition of IL-6 and TGF-beta to IL-23 further augmented ROR-gammat and ROR-alpha expression and suppressed Eomes expression, thereby enhancing IL-17 production by CD8 T cells. A loss of cytotoxic function accompanied the production of IL-17, as the addition of IL-6 and TGF-beta resulted in a marked reduction of granzyme B and perforin expression. Thus, CD8 T cells retain sufficient plasticity to respond to environmental cues and can acquire additional effector functions in response to their environmental context.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542449      PMCID: PMC2729917          DOI: 10.4049/jimmunol.0900939

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  IL-12p40: an inherently agonistic cytokine.

Authors:  Andrea M Cooper; Shabaana A Khader
Journal:  Trends Immunol       Date:  2006-11-28       Impact factor: 16.687

2.  IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype.

Authors:  Kerry A Casey; Matthew F Mescher
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

3.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor.

Authors:  Nikhil S Joshi; Weiguo Cui; Anmol Chandele; Heung Kyu Lee; David R Urso; James Hagman; Laurent Gapin; Susan M Kaech
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

4.  IL-12 and type-I IFN synergize for IFN-gamma production by CD4 T cells, whereas neither are required for IFN-gamma production by CD8 T cells after Listeria monocytogenes infection.

Authors:  Sing Sing Way; Colin Havenar-Daughton; Ganesh A Kolumam; Nural N Orgun; Kaja Murali-Krishna
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

5.  T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma.

Authors:  Xuexian O Yang; Bhanu P Pappu; Roza Nurieva; Askar Akimzhanov; Hong Soon Kang; Yeonseok Chung; Li Ma; Bhavin Shah; Athanasia D Panopoulos; Kimberly S Schluns; Stephanie S Watowich; Qiang Tian; Anton M Jetten; Chen Dong
Journal:  Immunity       Date:  2007-12-27       Impact factor: 31.745

6.  IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.

Authors:  Liang Zhou; Ivaylo I Ivanov; Rosanne Spolski; Roy Min; Kevin Shenderov; Takeshi Egawa; David E Levy; Warren J Leonard; Dan R Littman
Journal:  Nat Immunol       Date:  2007-06-20       Impact factor: 25.606

7.  Deviation from a strong Th1-dominated to a modest Th17-dominated CD4 T cell response in the absence of IL-12p40 and type I IFNs sustains protective CD8 T cells.

Authors:  Nural N Orgun; Meredith A Mathis; Christopher B Wilson; Sing Sing Way
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

8.  Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6.

Authors:  Shih-Jen Liu; Jy-Ping Tsai; Chia-Rui Shen; Yuh-Pyng Sher; Chia-Ling Hsieh; Yu-Ching Yeh; Ai-Hsiang Chou; Shu-Rung Chang; Kuang-Nan Hsiao; Feng-Wei Yu; Hsin-Wei Chen
Journal:  J Leukoc Biol       Date:  2007-05-15       Impact factor: 4.962

9.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

Authors:  John S Tzartos; Manuel A Friese; Matthew J Craner; Jackie Palace; Jia Newcombe; Margaret M Esiri; Lars Fugger
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

10.  Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells.

Authors:  Andrew M Intlekofer; Naofumi Takemoto; Charlly Kao; Arnob Banerjee; Felix Schambach; John K Northrop; Hao Shen; E John Wherry; Steven L Reiner
Journal:  J Exp Med       Date:  2007-08-13       Impact factor: 14.307

View more
  26 in total

1.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

2.  Functional heterogeneity of human tissue-resident memory T cells based on dye efflux capacities.

Authors:  Brahma V Kumar; Radomir Kratchmarov; Michelle Miron; Dustin J Carpenter; Takashi Senda; Harvey Lerner; Amy Friedman; Steven L Reiner; Donna L Farber
Journal:  JCI Insight       Date:  2018-11-15

3.  Rapamycin attenuates Tc1 and Tc17 cell responses in cigarette smoke-induced emphysema in mice.

Authors:  Hui Zhang; Xiu Zhou; Xin Chen; Yuanzhen Lin; Shilin Qiu; Yun Zhao; Qiya Tang; Yi Liang; Xiaoning Zhong
Journal:  Inflamm Res       Date:  2019-08-29       Impact factor: 4.575

4.  Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype.

Authors:  Norman Yeh; Nicole L Glosson; Nan Wang; Lynette Guindon; Carl McKinley; Hiromasa Hamada; Qingsheng Li; Richard W Dutton; Protul Shrikant; Baohua Zhou; Randy R Brutkiewicz; Janice S Blum; Mark H Kaplan
Journal:  J Immunol       Date:  2010-07-12       Impact factor: 5.422

5.  Evaluation of two mutants of Mycobacterium avium subsp. paratuberculosis as candidates for a live attenuated vaccine for Johne's disease.

Authors:  Kun Taek Park; Andrew J Allen; John P Bannantine; Keun Seok Seo; Mary J Hamilton; Gaber S Abdellrazeq; Heba M Rihan; Amanda Grimm; William C Davis
Journal:  Vaccine       Date:  2011-05-10       Impact factor: 3.641

6.  Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile Virus Clearance.

Authors:  Dhiraj Acharya; Penghua Wang; Amber M Paul; Jianfeng Dai; David Gate; Jordan E Lowery; Dobrivoje S Stokic; A Arturo Leis; Richard A Flavell; Terrence Town; Erol Fikrig; Fengwei Bai
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

7.  Respective IL-17A production by γδ T and Th17 cells and its implication in host defense against chlamydial lung infection.

Authors:  Hong Bai; Xiaoling Gao; Lei Zhao; Ying Peng; Jie Yang; Sai Qiao; Huili Zhao; Shuhe Wang; YiJun Fan; Antony George Joyee; Zhi Yao; Xi Yang
Journal:  Cell Mol Immunol       Date:  2016-10-31       Impact factor: 11.530

8.  Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses.

Authors:  Ritu Sarin; Xingxin Wu; Clara Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

9.  Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques.

Authors:  William D Cornwell; Mark G Lewis; Xiaoxuan Fan; Jay Rappaport; Thomas J Rogers
Journal:  J Neuroimmunol       Date:  2013-09-20       Impact factor: 3.478

10.  The chemokine receptor CXCR5 is pivotal for ectopic mucosa-associated lymphoid tissue neogenesis in chronic Helicobacter pylori-induced inflammation.

Authors:  Susann Winter; Christoph Loddenkemper; Anton Aebischer; Katrin Räbel; Kirstin Hoffmann; Thomas F Meyer; Martin Lipp; Uta E Höpken
Journal:  J Mol Med (Berl)       Date:  2010-08-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.